Skip to content

Menstrua Care Lotion to help reduce period pain, white discharge and excessive bleeding.

A Retrospective Analysis of the Data from the Focus Group - Non-Randomised, Single Arm, Non-Comparative, Open Label, Proof of Concept study conducted on Menstura Care Lotion of Nanic Wellness Pvt. Ltd. in Menstruating Females to Regulate Menstrual Cycle, Control Leucorrhea, Regulate Excessive Menstruation and Reduce Dysmenorhea. - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/093251
Enrollment
39
Registered
2025-08-19
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N946- Dysmenorrhea, unspecified Health Condition 2: N921- Excessive and frequent menstruation with irregular cycle Health Condition 3: N921- Excessive and frequent menstruation with irregular cycle Health Condition 4: N898- Other specified noninflammatory disorders of vagina

Interventions

None listed

Sponsors

Nanic Wellness Pvt Ltd
Lead Sponsor
Yellow Bricks Research Hub
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects who were willing to use Menstura Care Lotion to regulate Menstrual cycle, control Leucorrhea, regulate excessive menstruation and reduce dysmenorhea. 2. Subjects willing to give informed consent. 3. Subjects willing to give feedback of their own free will

Exclusion criteria

Exclusion criteria: 1. Subjects who could not give feedback for three menstrual cycles. 2. Subjects with known hypersensitivity to product ingredients.

Design outcomes

Primary

MeasureTime frame
1. Numerical Rating Scale : Pain : Reduction in pain levels. 2. Numerical Rating Scale : Bleeding Intensity : Reduction in bleeding intensity 3. Numerical Rating Scale : White Discharge : Reduction in discharge 4. Cycle Length : Reduction in cycle length 5. Feedback Treatment : Excellent response. Timepoint: Baseline End of Cycle 1 End of Cycle 2 End of Cycle 3

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr VT Sriraam

Yellow Bricks Research Hub

md@auroushealthcare.com9840909155

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026